NCT05978739 2023-10-25Evaluating Different Doses of Orelabrutinib in MCLInnoCare Pharma Inc.Phase 2 Unknown40 enrolled
NCT05076097 2021-11-11A Study of OLR in First-line Treatment of Mantle Cell LymphomaTianjin Medical University Cancer Institute and HospitalPhase 2 Unknown29 enrolled